Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in first-line gastric or gastroesophageal cancer. The AK104-302 trial ...
A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile. Analysts got an ...
Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of “non-self” tumor cells. However, in chronic ...
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line ...
Atezolizumab and stereotactic body radiation in metastatic, recurrent, or persistent cervical cancer: Results from a phase II multi-institutional study. The best overall response, PFS and OS in first- ...
Long-term outcomes in triple-negative breast cancers (TNBC) treated with talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT). This is an ASCO Meeting Abstract from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results